Global Angioimmunoblastic T-Cell Lymphoma Market- Dynamics
Key market players operating in the global angioimmunoblastic t-cell lymphoma market are receiving fast track approvals for their investigational drugs, which is expected to boost the market growth during the forecast period. For instance, in March 2020, Kura Oncology, Inc., a biopharmaceutical company announced that the U.S. Food and Drug Administration (FDA) granted fast track designation to the company’s leading drug tipifarnib for treating AITL patients. The drug is a potent, selective farnesyl transferase inhibitor which can be used as a monotherapy in relapsed or refractory AITL.
In addition, the growing number of research studies focused on evaluating new drugs and mechanism pathways is further driving the growth of global angioimmunoblastic t-cell lymphoma market. For instance, based on a May 2020, research study published in the American Association for Cancer Research, researchers conducted genomic studies in which they identified recurrent mutations in Ras homolog gene family, member A (RHOA) in around 50-70% individuals suffering with angioimmunoblastic t-cell lymphoma. Moreover, in the study they also showed the suppression of G17V RHOA by dasatinib, a multikinase inhibitor. Hence, the study concluded the targeting of TCR pathway for efficient development strategies against AITL.
Angioimmunoblastic T-Cell Lymphoma Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients